Cross-linked Biodegradable Vesicle for Targeted CpG Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating glioblastoma, a malignant brain cancer, face challenges due to the blood-brain barrier limiting the entry of immune adjuvants like CpG, leading to low efficacy and toxic side effects, especially with intracranial administration, which is accompanied by hydrocephalus and inflammation.
Innovation Solution
A vesicle formed by a cross-linked biodegradable polymer with an asymmetric membrane structure is used to encapsulate oligonucleotides that activate an immune response, allowing for targeted delivery through intravenous injection, overcoming the limitations of existing vesicle technologies by providing stable, long-circulating, and biocompatible drug carriers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intracranial administration is used to deliver immune adjuvant CpG, then the therapeutic effect is improved, but hydrocephalus and inflammation occur due to rapid diffusion into blood
Solution Approach 1:
The patent introduces a vesicle carrier as an intermediary between the immune adjuvant CpG and the tumor target. This vesicle protects CpG from rapid diffusion into blood, enabling targeted delivery to tumor cells while avoiding systemic immunotoxicity and side effects like hydrocephalus and inflammation
Solution Approach 2:
The patent uses a vesicle with a flexible membrane structure to encapsulate CpG. This flexible shell allows the adjuvant to be delivered directly to tumor cells through endocytosis while preventing premature release and rapid diffusion into the bloodstream that causes harmful side effects
2Ease of manufacture
If existing vesicle technology is used to deliver CpG, then the drug delivery system is established, but the loading efficiency is low and internal circulation is unstable
Solution Approach 1:
The patent optimizes the vesicle composition parameters, specifically using a cationic polymer with a specific molecular weight range (10-50 kDa) and charge density. These parameter changes enable high loading efficiency of anionic CpG through electrostatic interaction while maintaining stable internal circulation in vivo
Solution Approach 2:
The patent employs a composite vesicle structure combining cationic polymer, PEG chains, and targeting ligands. This composite material approach achieves both high drug loading efficiency through electrostatic complexation and stable circulation through PEGylation and active targeting
3Reliability
If high dose CpG is used for immunotherapy, then the immune response is enhanced, but immunotoxicity occurs
Solution Approach 1:
The vesicle acts as a mediator that enables effective immunotherapy at lower doses. By protecting CpG from degradation and preventing systemic distribution, the vesicle allows localized high concentration at the tumor site with lower overall dosage, thus enhancing immune response while avoiding immunotoxicity
Solution Approach 2:
The patent achieves local quality by concentrating the immune adjuvant CpG specifically at the tumor site through targeted vesicle delivery. This localized concentration provides strong immune stimulation where needed while minimizing systemic exposure and immunotoxicity
4Ease of manufacture
If vesicles are used as carriers, then the drug delivery system is established, but the uptake of tumor cells is low and drug concentration in cells is low
Solution Approach 1:
The patent applies preliminary action by pre-equipping the vesicle surface with targeting ligands (such as transferrin or antibodies) that specifically recognize tumor cell markers. This preliminary functionalization enables active targeting and significantly enhances tumor cell uptake before the vesicle reaches the tumor site
Solution Approach 2:
The patent uses a composite vesicle structure incorporating targeting ligands, PEG chains, and cationic polymer. This composite design combines passive targeting (via EPR effect), active targeting (via ligand-receptor interaction), and enhanced cellular internalization, thereby improving tumor cell uptake and intracellular drug concentration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vesicle system achieves high drug entrapment rates, avoids toxic side effects, and demonstrates significant therapeutic effects in mouse models by efficiently targeting tumor cells, prolonging survival and inhibiting weight loss, thus offering a promising platform for immunotherapy of brain tumors.
Implementation Method 1
the vesicle formed by a reversibly cross-linked biodegradable polymer with an asymmetric membrane structure is obtained by means of the self-assembly of a polymer, or the self-assembly of a polymer and a targeting polymer
Implementation Method 2
the polymer includes a hydrophilic chain segment, a hydrophobic chain segment and positively charged molecules
Implementation Method 3
the hydrophobic chain segment contains a disulfide five-membered cyclic carbonate unit
Data Source
AI summary
An anti-tumor nano adjuvant is obtained by loading a drug on the vesicle formed by a reversibly cross-linked biodegradable polymer with an asymmetric membrane structure; the drug is an oligonucleotide activating an immune response; the vesicle formed by the degradable polymer is obtained by the self-assembly of a polymer followed by cross-linking; the molecular chain of the polymer includes a hydrophilic chain segment, a hydrophobic chain segment and positively charged molecules, successively connected; the hydrophobic chain segment is a polycarbonate chain segment and/or a polyester chain segment, which is compounded and loaded with a drug by electrostatic interaction; and the membrane is a polycarbonate chain segment and/or a polyester chain segment, which is reversibly cross-linked, biodegradable and has good biocompatibility, the dithiolane in the side chain thereof is similar to thioctic acid, a natural antioxidant in human body, and the shell thereof is based on PEG and targets cancer cells.